McKesson Corporation is a global leader in healthcare supply chain management solutions, retail pharmacy, community oncology and specialty care, and healthcare information solutions. McKesson partners with pharmaceutical manufacturers, providers, pharmacies, governments and other organizations in healthcare to help provide the right medicines, medical products and healthcare services to the right patients at the right time, safely and cost-effectively. United by our ICARE shared principles, its employees work every day to innovate and deliver opportunities that make our customers and partners more successful - all for the better health of patients. McKesson has been named a 'Most Admired Company' in the healthcare wholesaler category by FORTUNE, a 'Best Place to Work' by the Human Rights Campaign Foundation, and a top military-friendly company by Military Friendly.

Company profile
Ticker
MCK
Exchange
Website
CEO
Brian Tyler
Employees
Incorporated
Location
Fiscal year end
Industry (SIC)
Former names
MCKESSON HBOC INC
SEC CIK
Corporate docs
Subsidiaries
McKesson Europe AG • McKesson Europe Holdings GmbH • McKesson Global Procurement & Sourcing Limited • McKesson International • McKesson Ireland Limited • McKesson Medical-Surgical Holdings Inc. • McKesson Medical-Surgical Inc. • McKesson Medical-Surgical Top Holdings Inc. • McKesson Plasma and Biologics LLC • McKesson Specialty Care Distribution LLC ...
IRS number
943207296
MCK stock data
News

Apple Up 25% Since June: Is It Time to Buy?
12 Aug 22
This Lesser-Known Stock Has Moved 35% Since My Last Update, Here's What I'm Waiting For Next
9 Aug 22
Credit Suisse Lifts Price Targets For Drug Distributors After Solid Q2 Performance
8 Aug 22
Credit Suisse Maintains Outperform on McKesson, Raises Price Target to $385
8 Aug 22
10 Health Care Stocks Whale Activity In Today's Session
5 Aug 22
Press releases
Thinking about trading options or stock in Micron Technology, Constellation Brands, Novavax, McKesson Corp, or Cigna?
9 Aug 22
McKesson Corporation Reports Fiscal 2023 First-Quarter Results
3 Aug 22
McKesson Raises Quarterly Dividend by 15% to $0.54 Per Share
25 Jul 22
Thinking about trading options or stock in Alibaba, Novavax, Wynn Resorts, McKesson, or Walmart?
11 Jul 22
Thinking about trading options or stock in Nvidia, Centene, McKesson, Humana, or Alibaba?
8 Jul 22
Analyst ratings and price targets
Current price
Average target
$381.60
Low target
$345.00
High target
$400.00
Credit Suisse
Maintains
$385.00
Mizuho
Maintains
$345.00
Baird
Maintains
$400.00
UBS
Maintains
$400.00
Deutsche Bank
Upgraded
$378.00
Calendar
3 Aug 22
12 Aug 22
31 Mar 23
Financial summary
Quarter (USD) | Jun 22 | Mar 22 | Dec 21 | Sep 21 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Annual (USD) | Mar 22 | Mar 21 | Mar 20 | Mar 19 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Cash burn rate (est.) | Burn method: Change in cash | Burn method: Operating income | Burn method: FCF (opex + capex) | Last Q | Avg 4Q | Last Q | Avg 4Q | Last Q | Avg 4Q |
---|---|---|---|---|---|---|
Cash on hand (at last report) | 2.34B | 2.34B | 2.34B | 2.34B | 2.34B | 2.34B |
Cash burn (monthly) | 531.67M | 16.25M | (no burn) | (no burn) | 313.67M | (no burn) |
Cash used (since last report) | 769.31M | 23.51M | n/a | n/a | 453.87M | n/a |
Cash remaining | 1.57B | 2.32B | n/a | n/a | 1.89B | n/a |
Runway (months of cash) | 3.0 | 142.6 | n/a | n/a | 6.0 | n/a |
Recent insider trades
Date | Owner | Security | Transaction | Code | Indirect | 10b5-1 | $Price | #Shares | $Value | #Remaining |
---|---|---|---|---|---|---|---|---|---|---|
22 Jul 22 | Richard H Carmona | RSU Common Stock | Grant | Acquire A | No | No | 0 | 606 | 0 | 606 |
22 Jul 22 | Webster Roy Dunbar | RSU Common Stock | Grant | Acquire A | No | No | 0 | 606 | 0 | 606 |
22 Jul 22 | James H. Hinton | RSU Common Stock | Grant | Acquire A | No | No | 0 | 606 | 0 | 606 |
22 Jul 22 | Kathleen Wilson-Thompson | RSU Common Stock | Grant | Acquire A | No | No | 0 | 606 | 0 | 606 |
22 Jul 22 | Linda Provie Mantia | RSU Common Stock | Grant | Acquire A | No | No | 0 | 606 | 0 | 606 |
Institutional ownership, Q1 2022
89.1% owned by funds/institutions
13F holders | Current |
---|---|
Total holders | 1103 |
Opened positions | 149 |
Closed positions | 109 |
Increased positions | 345 |
Reduced positions | 419 |
13F shares | Current |
---|---|
Total value | 38.84B |
Total shares | 128.08M |
Total puts | 1.77M |
Total calls | 1.53M |
Total put/call ratio | 1.2 |
Largest owners | Shares | Value |
---|---|---|
Vanguard | 15.44M | $4.73B |
BLK Blackrock | 11.57M | $3.54B |
STT State Street | 6.54M | $2.01B |
JPM JPMorgan Chase & Co. | 5.97M | $1.83B |
Massachusetts Financial Services | 5.63M | $1.72B |
FMR | 3.33M | $1.02B |
BRK.A Berkshire Hathaway | 2.92M | $894.5M |
Geode Capital Management | 2.86M | $872.7M |
PZN Pzena Investment Management | 2.7M | $827.31M |
IVZ Invesco | 2.53M | $775.4M |
Financial report summary
?Competition
Cardinal Health • VASO • Actavis • Omnicell • Exelixis • Henry Schein • Impax Laboratories • Medical Information Technology • Amerisource Bergen • Jazz PharmaceuticalsRisks
- We experience costly and disruptive legal disputes.
- We might experience losses not covered by insurance or indemnification.
- We experience costly legal disputes, government actions, and adverse publicity regarding our role in distributing controlled substances such as opioids.
- We might experience increased costs to distribute controlled substances such as opioids.
- We are subject to extensive, complex and challenging healthcare and other laws.
- We might lose our ability to purchase, compound, store or distribute pharmaceuticals and controlled substances.
- Privacy and data protection laws increase our compliance burden.
- Anti-bribery and anti-corruption laws increase our compliance burden.
- We might record significant charges from impairment to goodwill, intangibles and other assets or investments.
- We experience cybersecurity incidents that might significantly compromise our technology systems or might result in material data breaches.
- We might experience significant problems with information systems or networks.
- Our products or services might not conform to specifications or perform as we intend.
- We might not realize expected benefits from business process initiatives.
- We might be unable to successfully complete or integrate acquisitions or other business combinations.
- Exclusive forum provisions in our Bylaws could limit our stockholders’ ability to choose their preferred judicial forum for disputes with us or our directors, officers or employees.
- We might not realize the expected tax treatment from our split-off of Change Healthcare.
- We might be adversely impacted by outsourcing or similar third-party relationships.
- We may be unsuccessful in achieving our strategic growth objectives.
- We might be harmed by large customer purchase reductions, payment defaults or contract non-renewal.
- Our contracts with government entities involve future funding and compliance risks.
- Our participation in vaccination distribution programs may materially affect our operating results, reputation, and business.
- We might be harmed by changes in our relationships or contracts with suppliers.
- We might infringe intellectual property rights or our intellectual property protections might be inadequate.
- Our use of third-party data is subject to limitations that could impede the growth of our data services business.
- We might be unable to successfully recruit and retain qualified employees.
- We might be adversely impacted by healthcare reform such as changes in pricing and reimbursement models.
- We might be adversely impacted by competition and industry consolidation.
- We might be adversely impacted by changes or disruptions in product supply.
- We might be adversely impacted as a result of our distribution of generic pharmaceuticals.
- We might be adversely impacted by inflation, an economic slowdown, or recession.
- Disruption or other changes in capital and credit markets might impede access to credit and increase borrowing costs for us and our customers and suppliers and might impair the financial soundness of our customers and suppliers.
- We may have difficulties in sourcing or selling products due to a variety of causes.
- We might be adversely impacted by tax legislation or challenges to our tax positions.
- We might be adversely impacted by fluctuations in foreign currency exchange rates.
- We might be adversely impacted by events outside of our control, such as widespread public health issues, natural disasters, political events, and other catastrophic events.
- We may be adversely affected by global climate change or by legal, regulatory, or market responses to such change.
- We might be adversely impacted by changes in accounting standards.
Management Discussion
- Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations.
- Management’s discussion and analysis of financial condition and results of operations, referred to as the “Financial Review,” is intended to assist the reader in the understanding and assessment of significant changes and trends related to the results of operations and financial position of McKesson Corporation together with its subsidiaries (collectively, the “Company,” “McKesson,” “we,” “our,” or “us” and other similar pronouns). This discussion and analysis should be read in conjunction with the condensed consolidated financial statements and accompanying financial notes in Item 1 of Part I of this Quarterly Report on Form 10-Q (“Quarterly Report”) and in Item 8 of Part II of our Annual Report on Form 10-K for the fiscal year ended March 31, 2022 previously filed with the Securities and Exchange Commission on May 9, 2022 (“2022 Annual Report”).
- Our fiscal year begins on April 1 and ends on March 31. Unless otherwise noted, all references to a particular year shall mean our fiscal year.
Content analysis
?Positive | ||
Negative | ||
Uncertain | ||
Constraining | ||
Legalese | ||
Litigous | ||
Readability |
H.S. sophomore Avg
|
New words:
adequately, admit, analytical, assumed, avoid, binding, burden, chose, circumstance, colluding, commodity, conflict, created, dedicated, deemed, delay, Denmark, derecognized, difficult, disgorgement, diversified, divested, entry, failed, Fewer, Hart, hindsight, Holdco, impracticable, improved, inability, independent, innovative, knowingly, length, liable, lifecycle, lock, mentioned, military, minimize, mistrial, NG, objectively, Omni, preferable, principle, prohibit, purported, quality, release, released, Reliable, repackaged, restrain, retrospective, Russia, school, separate, Sherman, show, small, subdivision, talent, temperature, therapeutic, Ukraine, unrest, unsealing, voluntarily, waive, War, willfully, wrongdoing
Removed:
abstinence, acquisition, adequacy, administered, Administration, aforementioned, agree, Amendment, applying, appraisal, arrangement, assembled, awarded, borrowed, bound, broader, calculate, calculating, cancelled, captioned, cease, charitable, children, combining, commencing, commitment, community, comparing, conclude, consolidating, converting, death, decommissioning, deferred, deposit, direct, disbursed, discounted, dismissal, dismissed, domestic, donate, donation, drove, duration, Emergency, employee, enhanced, enter, enterprise, environment, estate, EURIBOR, exact, exceeded, expert, expiration, extinguishment, face, finalized, Food, foot, foreclose, foreclosed, full, FX, GmbH, hand, headcount, implemented, incur, infected, inflated, inflow, initially, initiated, insurance, intraperiod, Island, KGaA, largest, lesser, list, manufactured, mature, medical, methodology, Nassau, navigation, negatively, neonatal, November, obsolete, offer, Ohio, onset, Opiate, originally, outcome, owed, packing, patient, pendency, Pfizer, picking, pickup, playing, preparing, present, proportion, proportional, putative, qualified, qualitative, quantitative, rapidly, real, realignment, recognition, recommended, recovery, redeem, redeemed, reducing, reduction, reflecting, Regional, registration, rejecting, relate, RelayHealth, remained, reorganizing, repurpose, requiring, resale, resulted, retain, retired, return, Rhode, ruled, safely, safety, scheduled, seasonality, segregation, Simplifying, situation, strain, Stuttgart, subsequently, Suffolk, superseded, supported, supporting, swap, syndrome, telecommuting, temporarily, tender, thereto, traffic, travel, unadjusted, unaffiliated, unamortized, uncertain, unfavorably, utero, vi, vii, viral, warrant, WBA, weakened, worked, workplace, written, wrongful
Financial reports
Current reports
8-K
McKESSON CORPORATION REPORTS FISCAL 2023 FIRST-QUARTER RESULTS
3 Aug 22
8-K
Submission of Matters to a Vote of Security Holders
25 Jul 22
8-K
McKESSON REPORTS FISCAL 2022 FOURTH-QUARTER AND FULL-YEAR RESULTS
4 May 22
8-K
Departure of Directors or Certain Officers
29 Apr 22
8-K
McKesson’s Board of Directors Elects W. Roy Dunbar as New Director
1 Apr 22
8-K
Entry into a Material Definitive Agreement
25 Feb 22
8-K
Departure of Directors or Certain Officers
22 Feb 22
8-K
McKESSON REPORTS FISCAL 2022 THIRD-QUARTER RESULTS
2 Feb 22
8-K
McKesson’s Board of Directors Elects James H. Hinton and Kathleen Wilson-Thompson as New Directors
18 Jan 22
8-K
McKESSON REPORTS FISCAL 2022 SECOND-QUARTER RESULTS
1 Nov 21
Registration and prospectus
S-8
Registration of securities for employees
27 Jul 22
S-8
Registration of securities for employees
27 Jul 22
424B5
Prospectus supplement for primary offering
10 Aug 21
FWP
Free writing prospectus
10 Aug 21
424B3
Prospectus supplement
9 Aug 21
25-NSE
Exchange delisting
19 Jul 21
424B5
Prospectus supplement for primary offering
1 Dec 20
FWP
Free writing prospectus
30 Nov 20
425
Business combination disclosure
30 Nov 20
424B3
Prospectus supplement
30 Nov 20
Proxies
DEFA14A
Additional proxy soliciting materials
12 Jul 22
DEFA14A
Additional proxy soliciting materials
9 Jun 22
DEFA14A
Additional proxy soliciting materials
12 Jul 21
PX14A6G
Letter to shareholders
22 Jun 21
DEFA14A
Additional proxy soliciting materials
8 Jun 21
DEF 14A
Definitive proxy
8 Jun 21
DEFA14A
Additional proxy soliciting materials
8 Jul 20
PX14A6G
Letter to shareholders
26 Jun 20
PX14A6G
Letter to shareholders
23 Jun 20
Other
SD
Conflict minerals disclosure
1 Jun 22
UPLOAD
Letter from SEC
6 Jun 21
SD
Conflict minerals disclosure
28 May 21
CORRESP
Correspondence with SEC
1 Apr 21
UPLOAD
Letter from SEC
21 Mar 21
SD
Conflict minerals disclosure
31 May 18
CERT
Certification of approval for exchange listing
12 Feb 18
UPLOAD
Letter from SEC
28 Aug 17
CORRESP
Correspondence with SEC
17 Aug 17
CORRESP
Correspondence with SEC
20 Jul 17
Ownership
4
MCKESSON / DONALD R KNAUSS ownership change
26 Jul 22
4
MCKESSON / Dominic J Caruso ownership change
26 Jul 22
4
MCKESSON / Bradley E Lerman ownership change
26 Jul 22
4
MCKESSON / Maria Martinez ownership change
26 Jul 22
4
MCKESSON / Linda Provie Mantia ownership change
26 Jul 22
4
MCKESSON / SUSAN R SALKA ownership change
26 Jul 22
4
MCKESSON / James H. Hinton ownership change
26 Jul 22
4
MCKESSON / Kathleen Wilson-Thompson ownership change
26 Jul 22
4
MCKESSON / Webster Roy Dunbar ownership change
26 Jul 22
4
MCKESSON / Richard H Carmona ownership change
26 Jul 22
Patents
Utility
Method and apparatus for parsing and differently processing different portions of a request
26 Jul 22
A method, apparatus and computer program product modify messaging behavior based upon parsing and different processing of different portions of a request.
Utility
Systems and methods for determining and communicating a prescription benefit coverage denial to a prescriber
19 Jul 22
Systems and methods are provided for determining and communicating prescription benefit coverage information to a prescriber of the product, service, or medication.
Utility
Central fill facility and associated drug dispensing system and method
12 Jul 22
A central fill facility, drug dispensing system and method are provided in order to efficiently and accurately dispense a plurality of different drugs.
Utility
Apparatuses, systems, and methods for the automated retrieval and dispensing of articles
31 May 22
A method and apparatus for dispensing and retrieving products is provided.
Utility
Computing device and method for message construction and processing based upon historical data
3 May 22
A computing device, method and computer program product are provided to process messages received from a source and to construct messages transmitted to a recipient that include the information required to elicit the desired response.
Transcripts
2023 Q1
Earnings call transcript
4 Aug 22
2022 Q4
Earnings call transcript
5 May 22
2022 Q3
Earnings call transcript
3 Feb 22
2022 Q2
Earnings call transcript
2 Nov 21
2022 Q1
Earnings call transcript
5 Aug 21
2021 Q4
Earnings call transcript
7 May 21
2021 Q3
Earnings call transcript
2 Feb 21
2021 Q2
Earnings call transcript
3 Nov 20
2021 Q2
Earnings call transcript
3 Nov 20
2021 Q2
Earnings call transcript
3 Nov 20
Reddit threads
How’s everyone going YTD?
4 Aug 22
Daily Discussion Thread - August 03, 2022
3 Aug 22
Daily Discussion Thread - August 3rd, 2022
3 Aug 22
Yearly Dividend
2 Aug 22
Daily Discussion Thread - August 2nd, 2022
2 Aug 22
Daily Discussion Thread - August 1st, 2022
1 Aug 22
Earnings for the first week of August 2022! Expect plenty of oil/gas, fertilizer, pharma, semiconductors, restaurants, and more!
31 Jul 22
What are some stocks you plan to hold for the next 10-20 years?
7 Jul 22
Vasectomies: Urologist says consultations are up 900% after Roe v. Wade decision
30 Jun 22
229 S&P500 companies ($21.6t in market cap, 61.8%) report earnings in the next ~30 days
25 Jun 22